GlassScriptPhysician profile
Heather A Conn
NPI 1902248495
$3,295.01
in general payments reported to CMS, 2019-2025
18 companies · $987 in 2025
The $987 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $186 · 2022: $334 · 2023: $678 · 2024: $1,111 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $530.24 | 2023-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $521.05 | 2021-2025 | Verquvo, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $356.34 | 2021-2025 | Uptravi, Opsumit |
| Alnylam Pharmaceuticals INC. | $346.09 | 2023-2025 | Onpattro, Amvuttra |
| Janssen Pharmaceuticals, INC | $325.45 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $266.54 | 2021-2025 | |
| Pfizer INC. | $136.67 | 2022-2025 | |
| Amgen INC. | $129.77 | 2023-2025 | Repatha, Repatha |
| Cvrx, INC. | $117.74 | 2023-2025 | Barostim Neo System |
| Medtronic, INC. | $108.58 | 2022-2024 | Micra |
| Astrazeneca Pharmaceuticals LP | $99.69 | 2021-2024 | Farxiga |
| Scpharmaceuticals INC. | $79.17 | 2023-2025 | |
| Esperion Therapeutics, INC. | $67.76 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.57 | 2023-2024 | Lifevest |
| Abbott Laboratories | $47.16 | 2025 | Aveir |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $46.48 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.14 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $13.57 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.